Control of oncogenesis and cancer therapy resistance

British Journal of Cancer

Volumn 90, Issue 3, 2004, Pages 573-577

  Perona, R ^a   Sanchez Perez I ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

Apoptosis; Chemotherapy; Drug resistance; Oncogenes; Radiotherapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DOXORUBICIN; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; IMATINIB; LONAFARNIB; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RAPAMYCIN; TEMSIROLIMUS; TRASTUZUMAB;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CAUSE OF DEATH; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; DISEASE COURSE; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSFORMATION; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 1542299242     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601552     Document Type: Short Survey

References (30)

1. Ali IU, Schriml LM, Dean M (1999) Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932
2. Azzoli CG, Krug LM, Miller VA, Kris MG, Mass R (2002) Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 29: 59-65
3. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33: 162-167
4. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS (2002) The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62: 4307-4315
5. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22
6. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815
7. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y (1999) Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274: 31648-31654
8. Herbst RS, Langer CJ (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29: 27-36
9. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580
10. Hoover RR, Mahon FX, Melo JV, Daley GQ (2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100: 1068-1071
11. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092
12. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z (2003) Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89: 185-191
13. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310
14. Kim AH, Yano H, Cho H, Meyer D, Monks B, Margolis B, Birnbaum MJ, Chao MV (2002) Akt1 regulates a JNK scaffold during excitotoxic apoptosis. Neuron 35: 697-709
15. Lamb JA, Ventura JJ, Hess P, Flavell RA, Davis RJ (2003) JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 11: 1479-1489
16. Lebedeva IV, Su ZZ, Sarkar D, Fisher PB (2003) Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin Cancer Biol 13: 169-178
17. Liu ZG, Hsu H, Goeddel DV, Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87: 565-576
18. Luu Y, Bush J, Cheung Jr KJ, Li G (2002) The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/ caspase-9 pathway. Exp Cell Res 276: 214-222
19. Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC (2001) The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 11: 11-19
20. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314-10319
21. Nielsen LL, Maneval DC (1998) P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5: 52-63
22. Orlowski RZ, Baldwin Jr AS (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389
23. Prendergast GC (2001) Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer 1: 162-168
24. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234-3243
25. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR (1998) Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinogen 21: 81-86
26. Sanchez-Pérez I, Benitah SA, Martinez-Gomariz M, Lacal JC, Perona R (2002) Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell 13: 2933-2945
27. Sanchez-Pérez I, Perona R (1999) Lack of c-Jun activity increases survival to cisplatin. FEBS Lett 453: 151-158
28. Schuler M, Green DR (2001) Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 29: 684-688
29. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501
30. Witters LM, Santala SM, Engle L, Chinchilli V, Lipton A (2003) Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am J Clin Oncol 26: 50-54